A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer

71Citations
Citations of this article
60Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: We investigated whether the Src inhibitor saracatinib (AZD0530) improved efficacy of weekly paclitaxel in platinum-resistant ovarian cancer. Patients and methods: Patients with platinum-resistant ovarian, fallopian tube or primary peritoneal cancer were randomised 2: 1 to receive 8-week cycles of weekly paclitaxel (wPxl; 80 mg/m2/week ×6 with 2-week break) plus saracatinib (S; 175 mg o.d.) or placebo (P) continuously, starting 1 week before wPxl, until disease progression. Patients were stratified by taxane-free interval (<6 versus ≥6 months/no prior taxane). The primary end point was progression-free survival (PFS) rate at 6 months. Secondary end points included overall survival (OS) and response rate (RR). Results: A total of 107 patients, median age 63 years, were randomised. Forty-three (40%) had received >2 lines of prior chemotherapy. The 6-month PFS rate was 29% (wPxl + S) versus 34% (wPxl + P) (P = 0.582). Median PFS was 4.7 versus 5.3 months (hazard ratio 1.00, 95% confidence interval 0.65–1.54; P = 0.99). RR (complete + partial) was 29% (wPxl + S) versus 43% (wPxl + P), P value = 0.158. Grade 3/4 adverse events were 36% versus 31% (P = 0.624); the most frequent G3/4 toxicities were vomiting (5.8% saracatinib versus 8.6% placebo), abdominal pain (5.8% versus 0%) and diarrhoea (4.3% versus 5.7%). Febrile neutropenia was more common in the saracatinib arm (4.3%) than placebo (0%). Response, PFS and OS were all significantly (P < 0.05) better in patients with taxane interval ≥6 months/no prior taxane (n = 85) than those <6 months (n = 22), regardless of randomisation. Conclusions: Saracatinib does not improve activity of weekly paclitaxel in platinum-resistant ovarian cancer. Taxane-free interval of ≥6 months/no prior taxane was associated with better outcome in both groups. Trials registration: Clinicaltrials.gov NCT01196741; ISRCTN 32163062.

References Powered by Scopus

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial

1290Citations
N/AReaders
Get full text

Definitions for response and progression in ovarian cancer clinical trials incorporating recist 1.1 and CA 125 agreed by the gynecological cancer intergroup (GCIG)

528Citations
N/AReaders
Get full text

Phase II trial of weekly paclitaxel (80 mg/m<sup>2</sup>) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study

210Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial

160Citations
N/AReaders
Get full text

Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence

110Citations
N/AReaders
Get full text

Management of platinum-resistant, relapsed epithelial ovarian cancer and new drug perspectives

109Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

McNeish, I. A., Ledermann, J. A., Webber, L., James, L., Kaye, S. B., Hall, M., … Khan, I. (2014). A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer. Annals of Oncology, 25(10), 1988–1995. https://doi.org/10.1093/annonc/mdu363

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 23

66%

Researcher 8

23%

Lecturer / Post doc 3

9%

Professor / Associate Prof. 1

3%

Readers' Discipline

Tooltip

Medicine and Dentistry 20

63%

Biochemistry, Genetics and Molecular Bi... 5

16%

Pharmacology, Toxicology and Pharmaceut... 4

13%

Nursing and Health Professions 3

9%

Save time finding and organizing research with Mendeley

Sign up for free